Moreover, in a mice model of hepatic steatosis, changes in gut microbiota are associated with exacerbated hepatic steatosis and inflammation through portal influx of TLR4 and TLR9 agonists, leading to enhanced hepatic tumor-necrosis factor (TNF)-α expression that drives NASH progression [73]. Here, TNF is linked to metabolic dysfunction-associated steatohepatitis.